TAK-960 100mg 100mg | Purity Not Available
Adooq Bioscience
TAK-960 is a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity.
More Information Supplier PageSearch Results
TAK-960 10mg 10mg | Purity Not Available
Adooq Bioscience
TAK-960 is a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity.
More Information Supplier PageCEP-18770 50mg 50mg | Purity Not Available
Adooq Bioscience
CEP-18770 is a novel orally active proteasome inhibitor with a favorable tumor selectivity profile for the treatment of MM and other malignancies responsive to proteasome inhibition.
More Information Supplier PageCEP-18770 5mg 5mg | Purity Not Available
Adooq Bioscience
CEP-18770 is a novel orally active proteasome inhibitor with a favorable tumor selectivity profile for the treatment of MM and other malignancies responsive to proteasome inhibition.
More Information Supplier PageCEP-18770 10mM * 1mL in DMSO 10mM * 1mL in DMSO | Purity Not Available
Adooq Bioscience
CEP-18770 is a novel orally active proteasome inhibitor with a favorable tumor selectivity profile for the treatment of MM and other malignancies responsive to proteasome inhibition.
More Information Supplier PageCEP-18770 100mg 100mg | Purity Not Available
Adooq Bioscience
CEP-18770 is a novel orally active proteasome inhibitor with a favorable tumor selectivity profile for the treatment of MM and other malignancies responsive to proteasome inhibition.
More Information Supplier PageCEP-18770 10mg 10mg | Purity Not Available
Adooq Bioscience
CEP-18770 is a novel orally active proteasome inhibitor with a favorable tumor selectivity profile for the treatment of MM and other malignancies responsive to proteasome inhibition.
More Information Supplier PageTAK-960 50mg 50mg | Purity Not Available
Adooq Bioscience
TAK-960 is a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity.
More Information Supplier PageCCT239065 10mg 10mg | Purity Not Available
Adooq Bioscience
CCT239065 is a mutant protein kinase inhibitor that inhibits signaling downstream of V600EBRAF in cancer cells, blocking DNA synthesis, and inhibiting proliferation.
More Information Supplier PageCCT239065 100mg 100mg | Purity Not Available
Adooq Bioscience
CCT239065 is a mutant protein kinase inhibitor that inhibits signaling downstream of V600EBRAF in cancer cells, blocking DNA synthesis, and inhibiting proliferation.
More Information Supplier Page